Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CTAGE5/MIA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTAGE5/MIA2 Recombinant Protein (ECD/Specific Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View CTAGE5 Products |
| Gene Delivery | CTAGE5/MIA2 Promise-ORF / Lentivirus Full-length ORF lentiviral particles optimized for stable cell line generation and functional secretion assays. |
View CTAGE5 Products |
| Benchmark Ab | Anti-CTAGE5/MIA2 Recombinant Antibody High-affinity positive control clone for immunoprecipitation, flow cytometry, and Western blot validation. |
View CTAGE5 Products |
| Validator | CTAGE5/MIA2 siRNA Set Target-specific siRNA pool for knockdown verification in collagen export and cancer cell proliferation assays. |
View CTAGE5 Products |
| Related Target A | MIA3 (TANGO1) Essential interaction partner forming the TANGO1-CTAGE5 complex at ER exit sites to facilitate large cargo export. |
View MIA3 Products |
| Related Target B | COL1A1 (Collagen Type I Alpha 1) Primary cargo mediated by the CTAGE5/MIA3 complex; critical readout for anti-fibrotic drug screening. |
View COL1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER-membrane localization & conformational stability | Lentiviral transduction vectors designed for stable, native-conformation overexpression in host cell lines. |
| Protein-protein interaction (PPI) screening (CTAGE5-MIA3) | High-purity, sequence-verified recombinant domains (cytoplasmic/luminal) with precise tag options (His, GST, Fc). |
| Lack of reliable reference controls | Sequence-defined recombinant benchmark antibodies and validated siRNA pools included in the workflow. |
| False positives in high-throughput screening | Rigorous mass spectrometry verification and endotoxin control (<1.0 EU/μg) to prevent non-specific cellular toxicity. |
Live CTAGE5/MIA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CTAGE5/MIA2 axis represents a highly specialized frontier spanning cancer immunotherapy and anti-fibrotic medicine. Originally identified as a cutaneous T-cell lymphoma-associated antigen (CTAGE5) and a melanoma inhibitory activity gene family member (MIA2), its biological role has expanded significantly. CTAGE5 acts as a key co-factor for TANGO1 (MIA3), regulating the endoplasmic reticulum (ER) export of bulky cargo such as collagen and very-low-density lipoproteins (VLDL).
The race for CTAGE5/MIA2 therapeutics is intensifying, with major players shifting focus from traditional systemic cytostatics to targeted biologics and small-molecule protein-protein interaction (PPI) inhibitors. As first-generation diagnostic and prognostic tools reach clinical utility, the next wave of R&D is targeting the disruption of the ER-to-Golgi transport machinery in fibrotic diseases and the exploitation of CTAGE5 as a tumor-associated antigen in solid and hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Liver Fibrosis, Scleroderma | PPI Disruption Assay (Requires high-purity CTAGE5 cytoplasmic domain and MIA3 recombinant proteins) |
| Monoclonal Antibodies / ADCs | Oncology-focused Biopharma | Cutaneous T-Cell Lymphoma, HCC | Surface Expression & Internalization Assay (Requires Lentivirus for stable cell lines) |
| mRNA / RNAi Therapeutics | RNA Therapeutics Specialists | Hyperlipidemia, Fibrotic Disorders | Knockdown Verification (Requires validated siRNA sets and high-fidelity qPCR controls) |